PMID- 38302936
OWN - NLM
STAT- MEDLINE
DCOM- 20240205
LR  - 20240313
IS  - 1475-2840 (Electronic)
IS  - 1475-2840 (Linking)
VI  - 23
IP  - 1
DP  - 2024 Feb 1
TI  - Characterizing diabetic cardiomyopathy: baseline results from the ARISE-HF trial.
PG  - 49
LID - 10.1186/s12933-024-02135-z [doi]
LID - 49
AB  - BACKGROUND: Diabetic cardiomyopathy (DbCM) is a form of Stage B heart failure 
      (HF) at high risk for progression to overt disease. Using baseline 
      characteristics of study participants from the Aldose Reductase Inhibition for 
      Stabilization of Exercise Capacity in Heart Failure (ARISE-HF) Trial we sought to 
      characterize clinical characteristics of individuals with findings consistent 
      with DbCM. METHODS: Among study participants meeting inclusion criteria, clinical 
      characteristics, laboratory testing, imaging, Kansas City Cardiomyopathy 
      Questionnaire (KCCQ), Physical Activity Scale of the Elderly (PASE) and 
      cardiopulmonary exercise testing (CPET) results were tabulated. Cluster 
      phenogroups were identified. RESULTS: Among 691 study participants (mean age 67.4 
      years; 50% were female), mean duration of type 2 diabetes mellitus (T2DM) was 
      14.5 years. The median (Q1, Q3) N-terminal pro-B type natriuretic peptide and 
      high sensitivity cardiac troponin T were 71 (35, 135) ng/L and 9 [6, 12] ng/L. 
      The most common echocardiographic abnormalities were reduced global longitudinal 
      strain in 25.3% and impaired diastolic relaxation in 17.7%. Despite rather 
      well-preserved KCCQ scores the average PASE score was markedly impaired at 155 
      accompanied by an average maximal oxygen consumption of 15.7 mL/Kg/minute on 
      CPET. In K-means clustering, 4 phenogroups were identified including a 
      higher-risk group with more advanced age, greater elevation of cardiac 
      biomarkers, and more prevalent evidence for diastolic dysfunction and left 
      ventricular hypertrophy. CONCLUSIONS: Baseline data from the ARISE-HF Trial 
      provide clinical characterization of individuals with T2DM and features of stage 
      B HF, and may help clarify the diagnosis of DbCM. TRIAL REGISTRATION: ARISE-HF, 
      NCT04083339.
CI  - (c) 2024. The Author(s).
FAU - Januzzi, James L
AU  - Januzzi JL
AD  - Heart Failure Trials, Baim Institute for Clinical Research, Boston, MA, USA. 
      jjanuzzi@partners.org.
AD  - Cardiology Division, Massachusetts General Hospital, Harvard Medical School, 55 
      Fruit Street, 02114, Boston, MA, USA. jjanuzzi@partners.org.
FAU - Del Prato, Stefano
AU  - Del Prato S
AD  - Interdisciplinary Research Center 'Health Science', Sant'Anna School of Advanced 
      Studies, Pisa, Italy.
FAU - Rosenstock, Julio
AU  - Rosenstock J
AD  - Velocity Clinical Research at Medical City and University of Texas, Southwestern 
      Medical Center, Dallas, TX, USA.
FAU - Butler, Javed
AU  - Butler J
AD  - Baylor Scott and White Research Institute, , Dallas, TX, USA.
AD  - University of Mississippi, Jackson, MS, USA.
FAU - Ezekowitz, Justin
AU  - Ezekowitz J
AD  - Canadian VIGOUR Centre, University of Alberta, Edmonton, AB, Canada.
FAU - Ibrahim, Nasrien E
AU  - Ibrahim NE
AD  - Cardiology Division, Brigham and Women's Hospital, Harvard Medical School, 
      Boston, MA, USA.
FAU - Lam, Carolyn S P
AU  - Lam CSP
AD  - National Heart Centre Singapore and Duke-National University of Singapore, 
      Singapore, Singapore.
FAU - Marwick, Thomas
AU  - Marwick T
AD  - Baker Heart and Diabetes Institute, Melbourne, Australia.
AD  - Menzies Institute for Medical Research, Hobart, Australia.
FAU - Wilson Tang, W H
AU  - Wilson Tang WH
AD  - Department of Cardiovascular Medicine, Heart Vascular and Thoracic Institute, 
      Cleveland Clinic, Cleveland, OH, USA.
FAU - Liu, Yuxi
AU  - Liu Y
AD  - Cardiology Division, Massachusetts General Hospital, Harvard Medical School, 55 
      Fruit Street, 02114, Boston, MA, USA.
FAU - Mohebi, Reza
AU  - Mohebi R
AD  - Cardiology Division, Massachusetts General Hospital, Harvard Medical School, 55 
      Fruit Street, 02114, Boston, MA, USA.
FAU - Urbinati, Alessia
AU  - Urbinati A
AD  - Applied Therapeutics Inc, New York, NY, USA.
FAU - Zannad, Faiez
AU  - Zannad F
AD  - Universite de Lorraine, CIC Inserm and CHRU Nancy, Lorraine, France.
FAU - Perfetti, Riccardo
AU  - Perfetti R
AD  - Applied Therapeutics Inc, New York, NY, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT04083339
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20240201
PL  - England
TA  - Cardiovasc Diabetol
JT  - Cardiovascular diabetology
JID - 101147637
SB  - IM
MH  - Humans
MH  - Female
MH  - Aged
MH  - Male
MH  - *Diabetic Cardiomyopathies/diagnostic imaging/etiology
MH  - *Diabetes Mellitus, Type 2/complications/diagnosis/drug therapy
MH  - Stroke Volume
MH  - *Heart Failure/diagnosis
MH  - Hypertrophy, Left Ventricular
MH  - Ventricular Function, Left
PMC - PMC10835978
OTO - NOTNLM
OT  - Cardiomyopathy
OT  - Diabetes
OT  - Heart failure
COIS- Dr. Januzzi is a Trustee of the American College of Cardiology, is a Board member 
      of Imbria Pharmaceuticals, has received research support from Abbott, Applied 
      Therapeutics, HeartFlow Inc, Innolife and Roche Diagnostics, consulting income 
      from Abbott, AstraZeneca, Bayer, Beckman, Boehringer-Ingelheim, Janssen, 
      Novartis, Merck, and Roche Diagnostics, and participates in clinical endpoint 
      committees/data safety monitoring boards for Abbott, AbbVie, Bayer, CVRx, 
      Intercept, Pfizer and Takeda; Dr. Del Prato has served as president of 
      EASD/European Foundation for the Study of Diabetes (EFSD) (2020-2022); has 
      received research grants to the institution from AstraZeneca and Boehringer 
      Ingelheim; has served as advisor for Abbott, Applied Therapeutics, AstraZeneca, 
      Boehringer Ingelheim, Eli Lilly & Co., EvaPharma, Jiangsu Hengrui Pharmaceuticals 
      Co., Menarini International, Merck Sharpe & Dohme, Novartis Pharmaceutical Co., 
      Novo Nordisk, Sanofi and Sun Pharmaceuticals; and has received fees for speaking 
      from AstraZeneca, Boehringer Ingelheim, Eli Lilly & Co., Laboratori Guidotti, 
      Merck Sharpe & Dohme and Novo Nordisk. Dr. Rosenstock has served on scientific 
      advisory boards and received honorarium or consulting fees from Applied 
      Therapeutics, Biomea Fusion, Boehringer Ingelheim, Eli Lilly, Endogenex, Hanmi, 
      Novo Nordisk, Oramed, Regor, Sanofi, Scholar Rock, Structure Therapeutics, Terns 
      Pharma and Zealand; and has received grants/research support from Applied 
      Therapeutics, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hanmi, Merck, Oramed, 
      Novartis, Novo Nordisk, Pfizer and Sanofi. Dr. Butler is a consultant to Abbott, 
      American Regent, Amgen, Applied Therapeutic, AstraZeneca, Bayer, Boehringer 
      Ingelheim, Bristol Myers Squibb, Cardiac Dimension, Cardior, CVRx, Cytokinetics, 
      Edwards, Element Science, Innolife, Impulse Dynamics, Imbria, Inventiva, Lexicon, 
      Lilly, LivaNova, Janssen, Medtronics, Merck, Occlutech, Novartis, Novo Nordisk, 
      Pfizer, Pharmacosmos, Pharmain, Roche, Sequana, SQ Innovation, and Vifor; Dr. 
      Ezekowitz reports research support for trial leadership or grants from American 
      Regent, Applied Therapeutics, AstraZeneca, Bayer, Cytokinetics, Merck & Co, Novo 
      Nordisk, Otsuka; honoraria for consultancy from AstraZeneca, Bayer, Boehringer 
      Ingelheim, Novartis, Novo Nordisk, Otsuka; serves as an advisor to US2.ai....Dr. 
      Ibrahim reports consulting income from Cytokinetics and honoraria from Applied 
      Therapeutics; Dr. Tang is a consultant for Sequana Medical, Cardiol Therapeutics 
      Inc, Genomics plc, Zehna Therapeutics, Renovacor, Boston Scientific, WhiteSwell, 
      Kiniksa Pharmaceuticals, Intellia Therapeutics, CardiaTec Biosciences and has 
      received honorarium from Springer, Belvoir Media Group, and American Board of 
      Internal Medicine; Dr. Lam is supported by a Clinician Scientist Award from the 
      National Medical Research Council of Singapore; has Received research support 
      from NovoNordisk and Roche Diagnostics; has Served as consultant or on the 
      Advisory Board/ Steering Committee/ Executive Committee for Alleviant Medical, 
      Allysta Pharma, AnaCardio AB, Applied Therapeutics, AstraZeneca, Bayer, 
      Biopeutics, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, 
      CardioRenal, Cytokinetics, Darma Inc., EchoNous Inc, Eli Lilly, Impulse Dynamics, 
      Intellia Therapeutics, Ionis Pharmaceutical, Janssen Research & Development LLC, 
      Medscape/WebMD Global LLC, Merck, Novartis, Novo Nordisk, Prosciento Inc, Quidel 
      Corporation, Radcliffe Group Ltd., Recardio Inc, ReCor Medical, Roche 
      Diagnostics, Sanofi, Siemens Healthcare Diagnostics and Us2.ai; and serves as 
      co-founder & non-executive director of Us2.ai. Dr. Zannad reports personal fees 
      from 89bio, Applied Therapeutics, Bayer, Betagenon, Biopeutics, Boehringer, BMS, 
      CVRx, Cardior, Cambrian, Cereno pharmaceutical, Cellprothera, CEVA, Merck, 
      Northsea, Novartis, NovoNordisk, Otsuka, Owkin, Salubris, Servier, having stock 
      options at G3Pharmaceutical and equities at Cereno pharmaceutical, Cardiorenal, 
      Eshmoun Clinical research and being the founder of CVCT. Drs. Urbinati and 
      Perfetti are employees of Applied Therapeutics, Inc. the rest of the authors have 
      no disclosures.
EDAT- 2024/02/02 06:43
MHDA- 2024/02/05 06:43
PMCR- 2024/02/01
CRDT- 2024/02/02 00:03
PHST- 2023/11/02 00:00 [received]
PHST- 2024/01/15 00:00 [accepted]
PHST- 2024/02/05 06:43 [medline]
PHST- 2024/02/02 06:43 [pubmed]
PHST- 2024/02/02 00:03 [entrez]
PHST- 2024/02/01 00:00 [pmc-release]
AID - 10.1186/s12933-024-02135-z [pii]
AID - 2135 [pii]
AID - 10.1186/s12933-024-02135-z [doi]
PST - epublish
SO  - Cardiovasc Diabetol. 2024 Feb 1;23(1):49. doi: 10.1186/s12933-024-02135-z.